INKT
Mink Therapeutics Inc
NASDAQ: INKT · HEALTHCARE · BIOTECHNOLOGY
$11.81
+8.55% today
Updated 2026-04-29
Market cap
$55.32M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.93
Dividend yield
—
52W range
$6 – $76
Volume
0.4M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$39.00
+230.23%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-2.07M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.70B | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-27.99M | $-22.46M | $-10.78M | $-12.49M | $-2.60M |
| EPS | — | — | — | — | $-2.93 |
| Free cash flow | $-19.12M | $-15.84M | $-9.56M | $-5.93B | $-2.07M |
| Profit margin | -1.03% | — | — | — | — |
Peer comparison
Smart narrative
Mink Therapeutics Inc trades at $11.81. Our Smart Value Score of 16/100 indicates the stock is weak.
Frequently asked questions
What is Mink Therapeutics Inc's stock price?
Mink Therapeutics Inc (INKT) trades at $11.81.
Is Mink Therapeutics Inc overvalued?
Smart Value Score 16/100 (Grade F, Strong Sell).
What is the price target of Mink Therapeutics Inc (INKT)?
The analyst target price is $39.00, representing +230.2% upside from the current price of $11.81.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-1,239.00%
Beta0.35
50D MA$10.99
200D MA$13.47
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—